ERBB2 and hyperinsulinemic hypoglycemia, familial, 4: For the 51 remaining cases, 10 were treated with matched therapy according to the IHC results; trastuzumab containing chemotherapy for ERBB2 positivity (3+, n = 5), PI3Kβ inhibitor for PTEN loss (n = 1), pan-ERBB tyrosine kinase inhibitor, afatinib with paclitaxel (ClinicalTrials.gov Identifier: NCT02501603) for EGFR positivity (n = 2), and pembrolizumab-containing regimen, a monoclonal antibody to programmed cell death 1 (PD-1) inhibitor for MMR-deficiency (n = 2).